Leaked documents from provincial and municipal governments in China reveal a

slew of previously unreported severe adverse events related to COVID-19 vaccines

made and administered in China. Tellingly, one of the documents listing the
reactions came with an admonishment to not share that news with the public,
according to a report in The Epoch Times.
The revelation came just days before the World Health Organization (WHO)’s
planned April 26 review of the Sinovac COVID-19 vaccine for emergency use.

One document noted that “suspected group vaccination adverse reactions (include)
death, and severe disability of the recipients.” That appeared in the “Notice of
Further Strengthening the Safety Management of COVID-19 Vaccination,” issued
April 6 by the Leadership Team for Epidemic Response within the Hebei provincial
government.

That document was marked, “extra urgent, and non-disclosure to the public.” It
required agencies to “strengthen the monitoring and handling of the adverse
reactions that would have a major negative impact on society,” The Epoch Times
reported, showing a Chinese-language photo of the report.

A second report documented rashes, fever, nausea, diarrhea, chest tightness and
shortness of breath resulting from Chinese COVID-19 vaccinations. It was entitled
“Statistical Table of Adverse Reactions of COVID-19 Vaccines,” and listed adverse
events from Laishui Community Health Service Center of Laishui County at Baoding
City, also in Hebei province. It was issued April 8.

A third document detailed the 47-day (and counting) quarantine of an individual

who was fully vaccinated yet continued to test positive for the virus. Called the
“Request for Consultation with Provincial Experts on a Resident Surnamed Sui,” the
document was issued March 3 by the office of the Baoding municipal Leadership
Team for Response to the Epidemic.

As it details, Sui, a resident of the Lianchi District of the city of Baoding, received
two doses of a Chinese-made COVID-19 vaccine in December 2020, then traveled to
Germany. Upon return, he was quarantined at a centralized quarantine site. During
quarantine, Sui took five comprehensive tests, including CT, blood serum, nucleic
acid and routine blood tests. IgM antibodies, which denote a recent infection, were
found in the blood serum tests each time. At the time of the report, per China
policy, Sui was still quarantined and waiting for a negative test.

According to The Epoch Times, Chinese experts consulting on Sui’s case suggest
that the positive results for IgM may be a side effect of the vaccination. The reason,
they said, is that some individuals may test positive for half a year. Others given the
same vaccine may test negative. The difference depends upon their physical
condition.

Given Sui’s case, other adverse events in municipal and provincial reports within
China, and reports throughout the world regarding adverse events, the safety of
the Sinovac and Sinopharm vaccines is concerning.

Earlier in the year, Tao Lina. M.D., a Shanghai vaccine expert, posted the physician
manual for the vaccine, listing 73 adverse events associated with the Chinese vaccine.
He called it the “most unsafe vaccine in the world.” He retracted his statements a
few days later.
China’s COVID-19 vaccines have been distributed to at least 50 nations, and the list is
growing. As they roll out, various countries are compiling their own lists of mostly
minor side effects. For example, CNN Philippines reported that the most common
adverse events associated with Sinovac's COVID-19 vaccine are elevated blood
pressure, headache, injection site pain, dizziness and rash. Egypt reported similarly
minor side effects. Pakistan likewise reported no adverse side effects.
Since the Sinovac COVID-19 vaccine rollout, the vaccine also has been plagued by
disparate efficacy claims. As Reuters reported, Brazil claimed the Sinovac vaccine is
50.7% effective, just over the 50% mark required by the World Health Organization
and well below the 78% efficacy rate touted when the vaccine was announced in
China last January.
A real-world study from Chile announced by the Ministry of Health in a news
conference April 16, boosts efficacy rates to 67% in terms of preventing
symptomatic infection, 85% at preventing hospitalizations, 89% at preventing
admission to the intensive care unit and 80% at preventing death. That report,
however, did not specifically assess the vaccine against any of the emerging
variants.
The Global Times (the English edition of People’s Daily – the official publication of
the Chinese Communist Party’s Central Committee), in late April claimed an adverse
event rate of 1.06% among the more than 519,000 people inoculated by December
1, 2020. That was far lower than the 13% and 19% rates reported in Phase II trials.
Gao Fu, director of China’s Center for Disease Control and Prevention, admitted the
low efficacy rates of China’s vaccines in a surprising statement at China’s National
Vaccine and Health Conference April 10. Consequently, he said, “It’s now under
consideration whether we should use different vaccines from different technical
lines for the immunization process.” A few days later, he walked back his
comments, saying they were misunderstood and actually applied to vaccines
globally.
So far, China has administered 216.08 million COVID-19 vaccines, according to data
released by the National Health Commission April 24, 2021.

Most Read Today

 Merck's Blockbuster Keytruda Tries Again with New Data for TNBC Approval
 Israeli Company Grabs $28.5 Million for Restorative Cystic Fibrosis Treatment
 The Latest News in the Battle Against COVID-19
 Monoclonal Antibody Proves Worth in Asthma Study
 No Chemicals, Heat or Irradiation Needed for Aphios’ Viral Inactivation Tech